OncoSec Medical Incorporated (NASDAQ:ONCS) saw a large growth in short interest in October. As of October 31st, there was short interest totalling 1,746,675 shares, a growth of 203.3% from the October 13th total of 575,924 shares. Based on an average trading volume of 2,088,182 shares, the short-interest ratio is presently 0.8 days. Currently, 6.3% of the company’s stock are sold short.

Several equities analysts have recently weighed in on the company. ValuEngine cut OncoSec Medical from a “sell” rating to a “strong sell” rating in a report on Monday, October 2nd. Maxim Group restated a “buy” rating and issued a $5.00 price objective on shares of OncoSec Medical in a report on Friday, September 1st. Finally, HC Wainwright restated a “buy” rating and issued a $6.00 price objective on shares of OncoSec Medical in a report on Thursday, November 9th. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the company. OncoSec Medical has an average rating of “Buy” and an average target price of $5.33.

OncoSec Medical (ONCS) opened at $2.22 on Thursday. OncoSec Medical has a 1-year low of $0.88 and a 1-year high of $2.95.

OncoSec Medical (NASDAQ:ONCS) last posted its quarterly earnings results on Wednesday, October 25th. The biotechnology company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.05). research analysts predict that OncoSec Medical will post -0.86 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This news story was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.thecerbatgem.com/2017/11/16/oncosec-medical-incorporated-oncs-sees-large-growth-in-short-interest.html.

About OncoSec Medical

OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation.

Receive News & Stock Ratings for OncoSec Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical Incorporated and related stocks with our FREE daily email newsletter.